Loading
Latest filing published 18 Apr 2023 for Timber Pharmaceuticals, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Lubor Gaal (board member) discloses dealings in Timber Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 15 April 2022 to 15 April 2023, the count stands at 2 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 18 April 2023, the filings show a share grant in Timber Pharmaceuticals, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations